Gemini Therapeutics (Nasdaq: GMTX) has appointed Brian Piekos as Chief Financial Officer, bringing over 20 years of financial and industry experience. Under CEO Jason Meyenburg's leadership, Gemini aims to develop first-in-class medicines for genetically defined age-related macular degeneration (AMD). Piekos, formerly with AMAG Pharmaceuticals, emphasizes the promise of their lead program, GEM103, targeting genetically-defined AMD patients. Approximately 40% of dry AMD patients possess risk variants in the complement factor H gene, highlighting the need for treatments like GEM103.
Gemini Therapeutics has completed a business combination with FS Development Corp., leading to its listing on the Nasdaq under the symbol GMTX. The merger generated approximately $216 million in gross proceeds, with $121 million from FSDC’s trust and $95 million from PIPE financing. CEO Jason Meyenburg expressed excitement about their focus on innovative treatments for age-related macular degeneration (AMD). Gemini’s lead candidate, GEM103, targets genetically defined AMD patients, aiming to address unmet medical needs.